Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Blood advances - 12 Nov 2019

Maffioli Margherita, Giorgino Toni, Mora Barbara, Iurlo Alessandra, Elli Elena, Finazzi Maria Chiara, Caramella Marianna, Rumi Elisa, Carraro Maria Cristina, Polverelli Nicola, D'Adda Mariella, Malato Simona, Rossi Marianna, Molteni Alfredo, Vismara Alessandro, Sissa Cinzia, Spina Francesco, Anghilieri Michela, Cattaneo Daniele, Renso Rossella, Bellini Marta, Pioltelli Maria Luisa, Cavalloni Chiara, Barraco Daniela, Accetta Raffaella, Bertù Lorenza, Della Porta Matteo Giovanni, Passamonti Francesco

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Italy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation Rate

Share to Neoplasms, Second Primary

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 31698448
DOI: 10.1182/bloodadvances.2019000646
PMCID: PMC6855128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.PMID 31698448Read ↗

Second Primary Malignancies in Chronic Myeloid LeukemiaSemantic proximity Read ↗

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosisSemantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.Semantic proximity Read ↗

Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.Semantic proximity Read ↗

Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Semantic proximity Read ↗

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.